Biohit: Difference between revisions

Biohit Oyj
Company type	Julkinen osakeyhtiö
Traded as	Nasdaq Helsinki: BIOBV.B
Industrie	Medical equipment
Gegründet	1988; 36 years ago
Gründer	Osmo Suovaniemi
Hauptsitz	Helsinki, Finland
Area served	Worldwide
Key people	Osmo Suovaniemi (Founder and Chairman of the Board), Semi Korpela (President and CEO)
Produkte	Diagnostics and medical devices (Acetium products for acid free stomach and smoking cessation)
Total equity	€15.5 million (2019)
Number of employees	40 in Finland, 10 in subsidiaries
Website	www.biohithealthcare.com

Browse history interactively

← Previous edit

Content deleted Content added

VisualWikitext

Inline

Latest revision as of 10:58, 5 April 2024

Biohit Oyj is a Finnish company which develops, manufactures, and markets biotech and diagnostics products for use in research and health care.

Summary

Biohit was established in 1988 in Finland by Professor Osmo Suovaniemi (M.D., Ph.D.), previously known as the founder of Labsystems [fi].^[1]^[2] He stepped down from the CEO position in June 2011, but remains actively involved with the company through positions on several advisory boards. Biohit is a globally operating Finnish biotechnology company. Biohit is headquartered in Helsinki and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) has been quoted on NASDAQ OMX Helsinki since 1999, Small cap/Healthcare. Semi Korpela was appointed CEO in 2011.

Markets

Biohit's two businesses are acetaldehyde-eliminating products and diagnostics. More than 90% of Biohit's sales occur outside Finland.^[3]

Diagnostic tests

The diagnostic product range of Biohit includes the GastroPanel examinations, which are used to aid diagnosis of Helicobacter pylori infection and atrophic gastritis from a blood sample. They are also ideal tools for the identification of patients at increased risk of gastric cancer, peptic ulcer disease, gastroesophageal reflux disease (GERD), and deficiencies of vitamin B12, calcium, and iron. In addition to this, Biohit offers Quick tests for the detection of

Lactose intolerance
Helicobacter pylori infection
Celiac disease
Screening of colorectal cancer

Acetaldehyde binding products

In 2018 was launched a new, nicotine-free smoking cessation product, Acetium Lozenge.

Monoclonal antibodies

Biohit also develops and manufactures monoclonal antibodies for research use and use as raw materials for the diagnostic industry.

Instruments

Adopting a systems approach, Biohit also provides laboratory equipment, such as microplate instruments and automates, as well as liquid handling products to support Biohit ELISA tests.

Distribution network

A network of 40 distributors, including 2 subsidiaries, in more than 40 countries is selling Biohit products. In the U.S. the official distributor is Bio Testing Supplies, a division of Avrio Genetics.^{[citation needed]}

Research, development, and intellectual property

Biohit spends roughly 30% of net sales on basic research each year and pursues an aggressive patenting strategy.^[4]

References

^ Harriet Öster (8 October 1998). "Labsystems kasvaa suuren suojassa". Tekniikka & Talous. Retrieved 2009-11-15.^{[permanent dead link]}
^ Osmo Suovaniemi, Helena Hentola (2004). "Aggressive Innovation and Patenting Strategy – the Way to Success and National Well-Being" (PDF). Biohit. Archived from the original (PDF) on 2011-11-10. Retrieved 2013-03-02.
^ Biohit Oyj. Annual Report 2019
^ Reuters. Overview of Biomet Oyj. [1]

External links

Official website

[1] Harriet Öster (8 October 1998). "Labsystems kasvaa suuren suojassa". Tekniikka & Talous. Retrieved 2009-11-15.^{[permanent dead link]}

[2] Osmo Suovaniemi, Helena Hentola (2004). "Aggressive Innovation and Patenting Strategy – the Way to Success and National Well-Being" (PDF). Biohit. Archived from the original (PDF) on 2011-11-10. Retrieved 2013-03-02.

[annual_report_2013-3] Biohit Oyj. Annual Report 2019

[4] Reuters. Overview of Biomet Oyj. [1]

[1]

[2]

[3]

[4]

@@ Line 1: / Line 1: @@
+{{Short description|Finnish biotechnology company}}
 {{Infobox company
 | name             = Biohit Oyj
-| type     = Public ({{OMX|HEX24241|BIOBV.B}})
+| type             = [[Julkinen osakeyhtiö]]
+| traded_as        = {{OMX|HEX24241|BIOBV.B}}
+| founded          = {{Start date and age|1988}}
 | founder          = Osmo Suovaniemi
 | location         = [[Helsinki]], [[Finland]]
 | area_served      = Worldwide
-| key_people       = Osmo Suovaniemi <small>([[Entrepreneur|Founder]] and [[Chairman of the Board]])</small>, Semi Korpela <small>([[President]] and [[Chief Executive Officer|CEO]])</small>
+| key_people       = Osmo Suovaniemi <small>([[Entrepreneur|Founder]] and [[Chairman of the Board]])</small>, Semi Korpela <small>([[President (corporate title)|President]] and [[Chief Executive Officer|CEO]])</small>
-| employees        = about 419
+| num_employees    = 40 in Finland, 10 in subsidiaries
 | industry         = [[Medical equipment]]
+| products         = Diagnostics and medical devices (Acetium products for acid free stomach and smoking cessation)
-| products         = [[Pipette|liquid handling equipment]]
-| equity           = €23.9 million <small>(2010)</small>
+| equity           = €15.5 million <small>(2019)</small>
+| website          = {{URL|https://www.biohithealthcare.com/}}
 }}
-'''Biohit Oyj''' is a Finnish company which develops, manufactures, and markets diagnostics products for use in [[research]] and [[health care]].
+'''Biohit Oyj''' is a Finnish company which develops, manufactures, and markets biotech and diagnostics products for use in [[research]] and [[health care]].
 ==Summary==
-Biohit was established in 1988 in [[Finland]] by Professor Osmo  Suovaniemi (M.D., Ph.D.), previously known as the founder of [[Labsystems]].<ref>{{Cite journal |author = Harriet Öster |date = 8.10.1998 |title = Labsystems kasvaa suuren suojassa |journal = Tekniikka & Talous |url = http://www.tekniikkatalous.fi/uutiset/article28510.ece |accessdate = 2009-11-15 }}</ref><ref>{{Cite web |title=Aggressive Innovation and Patenting Strategy – the Way to Success and National Well-Being |author=Osmo Suovaniemi, Helena Hentola |publisher=Biohit |year=2004 |url=http://www.biohit.com/resource/files/media/articles/biohit-innovation-patenting-strategy.pdf }}</ref> He stepped down from the CEO position in June 2011, but remains actively involved with the company through positions on several advisory boards. Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health”. Biohit is headquartered in Helsinki and has subsidiaries in Italy and the UK. Biohit’s Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki since 1999, Small cap/Healthcare. Mr Semi Korpela was appointed CEO in 2011.
+Biohit was established in 1988 in [[Finland]] by Professor Osmo Suovaniemi (M.D., Ph.D.), previously known as the founder of {{ill|Labsystems (Finnish company)|fi|Labsystems|lt=Labsystems}}.<ref>{{Cite journal |author = Harriet Öster |date = 8 October 1998 |title = Labsystems kasvaa suuren suojassa |journal = Tekniikka & Talous |url = http://www.tekniikkatalous.fi/uutiset/article28510.ece |accessdate = 2009-11-15 }}{{Dead link|date=July 2020 |bot=InternetArchiveBot |fix-attempted=yes }}</ref><ref>{{Cite web |title=Aggressive Innovation and Patenting Strategy – the Way to Success and National Well-Being |author=Osmo Suovaniemi, Helena Hentola |publisher=Biohit |year=2004 |url=http://www.biohit.com/resource/files/media/articles/biohit-innovation-patenting-strategy.pdf |access-date=2013-03-02 |archive-url=https://web.archive.org/web/20111110184424/http://www.biohit.com/resource/files/media/articles/biohit-innovation-patenting-strategy.pdf |archive-date=2011-11-10 |url-status=dead }}</ref> He stepped down from the CEO position in June 2011, but remains actively involved with the company through positions on several advisory boards. Biohit is a globally operating Finnish biotechnology company. Biohit is headquartered in Helsinki and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) has been quoted on [[NASDAQ OMX Helsinki]] since 1999, Small cap/Healthcare. Semi Korpela was appointed CEO in 2011.
-Biohit's operations are based on a goal-oriented and long-term innovation and patenting strategy. Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations that can be used to develop safe and cost-effective diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract.
-Biohit´s research and development combines expertise in various fields into integrated know-how. Biohit’s personnel together with scientific advisers representing various academic communities apply their knowledge in basic and applied research to develop innovative products for laboratories and the health care industry. The multidisciplinary approach, innovations and application has produced valuable results for the advancement of research and health care all over the world. A further strength of Biohit’s multidisciplinary R & D is the ability to react quickly to new customer needs and product ideas.
-All of Biohit’s products and processes from R&D to production and from marketing to sales comply with ISO 13485 quality standards, which cover the manufacture of medical device, and also with ISO 9001 and ISO 14001 quality and environmental standards. Biohit’s products are also CE/IVD (In Vitro Diagnostics) registered and approved.
-Biohit manufactures almost all of its products itself, using clean rooms, demanding raw materials.
-•The Quality Management System of Biohit complies with the ISO 9001 and the ISO 13485
-•The Biohit Environmental Quality Management complies with the ISO 14001 Environmental standard.
-•Certified by Det Norske Veritas (DNV)
 ==Markets==
-Biohit's two businesses are acetaldehyde eliminating products and diagnostics.  More than 90% of Biohit's sales occur outside Finland <ref name="annual_report_2013">Biohit Oyj. Annual Report 2012</ref>
+Biohit's two businesses are acetaldehyde-eliminating products and diagnostics. More than 90% of Biohit's sales occur outside Finland.<ref name="annual_report_2013">Biohit Oyj. Annual Report 2019</ref>
-Diagnostic tests
-The diagnostic product range of Biohit includes the GastroPanel examinations, which are used to aid diagnosis of Helicobacter pylori infection and atrophic gastritis from a blood sample. They are also ideal tools for identification of patients at increased risk of gastric cancer, peptic ulcer disease, gastroesophageal reflux disease (GERD) and deficiencies of vitamin B12, calcium and iron. In addition to this, Biohit offers Quick tests for the detection of
-•Lactose intolerance
-•Helicobacter pylori infection
-•Celiac disease
-•Screening of colorectal cancer
-Acetaldehyde binding products
-An acid-free stomach is the primary risk factor in gastric cancer. According to recent research, it is also a significant risk factor in oesophageal cancer. Acetium® is a CE marked product developed and patented by Biohit Oyj. It is intended for persons with a low-acid or anacidic stomach
+===Diagnostic tests===
-Monoclonal antibodies
+The diagnostic product range of Biohit includes the GastroPanel examinations, which are used to aid diagnosis of ''[[Helicobacter pylori]]'' infection and [[atrophic gastritis]] from a blood sample. They are also ideal tools for the identification of patients at increased risk of gastric cancer, peptic ulcer disease, gastroesophageal reflux disease (GERD), and deficiencies of vitamin B12, calcium, and iron. In addition to this, Biohit offers Quick tests for the detection of
+*[[Lactose intolerance]]
+*''Helicobacter pylori'' infection
+*[[Celiac disease]]
+*Screening of [[colorectal cancer]]
+===Acetaldehyde binding products===
-Biohit also develops and manufactures monoclonal antibodies for research use and use as raw materials for diagnostic industry.
+In 2018 was launched a new, nicotine-free smoking cessation product, Acetium Lozenge.
+===Monoclonal antibodies===
-Instruments
+Biohit also develops and manufactures monoclonal antibodies for research use and use as raw materials for the diagnostic industry.
+===Instruments===
 Adopting a systems approach, Biohit also provides laboratory equipment, such as microplate instruments and automates, as well as liquid handling products to support Biohit ELISA tests.
-===Distribution Network===
+===Distribution network===
-A network of 40 [[distributor]]s, including 2 subsidiaries, in more than 40 countries is selling Biohit products.<ref name="annual report 2010"/>
+A network of 40 [[distributor]]s, including 2 subsidiaries, in more than 40 countries is selling Biohit products. In the U.S. the official distributor is [https://biotestingsupplies.com/ Bio Testing Supplies], a division of [https://avriogenetics.com/ Avrio Genetics].{{Citation needed|date=January 2015}}
-==Research, Development, and Intellectual Property==
+==Research, development, and intellectual property==
-Biohit spends roughly 30% of net sales on [[basic research]] each year and pursues an aggressive [[patenting]] strategy.<ref>Reuters.  Overview of Biomet Oyj. http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=BIOBV.HE</ref>
+Biohit spends roughly 30% of net sales on [[basic research]] each year and pursues an aggressive [[patenting]] strategy.<ref>Reuters. Overview of Biomet Oyj. [https://web.archive.org/web/20141024141219/http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=BIOBV.HE] </ref>
 == References ==
-<!--- See [[Wikipedia:Footnotes]] on how to create references using <ref></ref> tags which will then appear here automatically -->
 {{Reflist}}
-== External links ==
+==External links==
-* [http://www.biohit.com/ Biohit]
+* {{Official website|https://www.biohithealthcare.com/}}
+{{Nasdaq Helsinki}}
 [[Category:Companies established in 1988]]
-[[Category:Companies of Finland]]
+[[Category:Biotechnology companies of Finland]]
 [[Category:Chemical companies of Finland]]
-[[Category:Articles created via the Article Wizard]]
+[[Category:Companies listed on Nasdaq Helsinki]]
-[[Category:Companies listed on the Helsinki Stock Exchange]]